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Abstract
Background: Leukemia is a clonal disorder characterized by uncontrolled proliferation of
haematopoietic cells, and represents the most common form of cancer in children. Advances in
therapy for childhood leukemia have relied increasingly on the use of high-dose chemotherapy
often combined with stem-cell transplantation. Despite a high success rate and intensification of
therapy, children still suffer from relapse and progressive disease resistant to further therapy. Thus,
novel forms of therapy are required.
Methods: This study focuses on dendritic cell (DC) vaccination of childhood leukemia and
evaluates the in vitro efficacy of different strategies for antigen loading of professional antigen-
presenting cells. We have compared DCs either loaded with apoptotic leukemia cells or
transfected with mRNA from the same leukemia cell line, Jurkat E6, for their capacity to induce
specific CD4+ and CD8+ T-cell responses. Monocyte-derived DCs from healthy donors were
loaded with tumor antigen, matured and co-cultured with autologous T cells. After one week, T-
cell responses against antigen-loaded DCs were measured by enzyme-linked immunosorbent spot
(ELISPOT) assay.
Results: DCs loaded with apoptotic Jurkat E6 cells or transfected with Jurkat E6-cell mRNA were
both able to elicit specific T-cell responses in vitro. IFNγ-secreting T cells were observed in both
the CD4+ and CD8+ subsets.
Conclusion: The results indicate that loading of DCs with apoptotic leukemia cells or transfection
with tumour mRNA represent promising strategies for development of cancer vaccines for
treatment of childhood leukemia.
Background
Leukemia represents the most common form of cancer in
children. There are two main types of childhood leuke-
mia, acute lymphoblastic leukemia (ALL) and acute
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childhood leukemia has improved continuously over the
past decades [1], and today disease-free survival is 70%–
80% for ALL and 40%–60% for AML [2-4]. In the Nordic
countries the overall event-free survival in ALL has risen
from 57% to75% [2]. However, in children with high-risk
ALL, the progress has only been modest. The relapse rate
has decreased in parallel with the improving results, but
the prognosis after relapse has not improved. Only 25%–
30% of children who relapse will reach and remain in a
second remission. Children with AML have a worse prog-
nosis than those with ALL. Event-free survival for AML is
below 55%, whereas the cure rate for children with ALL is
near 80%. The complete remission rate differs also, with
5%–10% induction failures due to refractory disease and
toxicity in AML, compared to 1%–2% in ALL [2].
Immunotherapy based on vaccination with dendritic cells
(DCs) has emerged as an attractive new form of therapy
for cancer in general, and DC-based vaccines have already
shown promise in follicular non-Hodgkin's lymphoma,
and in other hematological malignancies [5-7]. DCs are
antigen-presenting cells (APCs) specialized to induce T-
cell responses against cells exposing foreign peptides,
including tumour-related antigens, in context of MHC
molecules [8,9]. DCs reside in tissues in an immature
form, where they capture antigens from the environment.
After antigen capture, and in response to inflammatory
stimuli, DCs mature and migrate to lymph nodes to initi-
ate immunity [9]. Maturation of DCs is associated with up
regulation of the co-stimulatory molecules CD80 and
CD86, increased expression of HLA molecules, enhance-
ment of their APC function, and expression of CCR7
chemokine receptors that promote migration to the T-cell
area in lymph nodes [10]. In several animal studies, it has
been shown that immunization with cancer-antigen
loaded DCs efficiently primes both CD4+ and CD8+ T-
cells, resulting in protective immunity against tumours
[11-16].
Vaccination with tumor antigen-loaded DCs has been
shown to induce both Th and CTL responses, and tumor
regression in some patients [16,17]. An important issue in
optimizing DC vaccines is the choice of tumour antigen
for loading of DCs. Several clinical trials in patients with
melanoma have demonstrated that vaccination against a
single antigen can induce tumour specific CTLs [18].
However, for many tumours no specific cancer antigens
are known. For such patients, autologous tumor cells or
tumor cell lines containing a repertoire of antigens over-
lapping with the repertoire in the patient's tumor, repre-
sents an alternative source of antigens. Effective cross-
priming with antigens from tumour cells has been dem-
onstrated with apoptotic cancer cells [19-21]. Transfer of
whole tumor mRNA into DCs represents an alternative
way of loading DCs. The transfected mRNA can be
expressed for a relatively long period of time [22-24] and
give rise to specific T-cell responses in vitro and following
vaccination of patients [25]. So far, no studies on the rel-
ative efficacy of these two antigen loading methods have
been performed. The aim of the present study was to com-
pare DCs either loaded with apoptotic Jurkat E6 cells or
transfected with mRNA isolated from Jurkat E6 cells, for
their ability to generate T-cell responses against antigens
derived from the human T-cell line. The Jurkat leukaemic
T-cell line is a reference cell line [26], and was chosen as a
source of antigen in the model experiments described
here. We demonstrate that both strategies can be success-
fully employed to induce T helper and CTL responses
against antigens derived from allogeneic leukemic T-cells.
Methods
Cytokines and chemicals
GM-CSF was purchased from Novartis (Basel, Switzer-
land), IL-4, TNFα, IL1β and IL-6 from CellGenix
(Freiburg, Germany), and Prostaglandin E2 (PgE2), IL-7,
IL-2 and IL-12 from R&D Systems (Minneapolis, USA).
Staurosporin was obtained from (Sigma Aldrich, Saint
Louise, Missouri).
Preparation of DCs and T cells
PBMC from healthy donors (obtained from Buskerud
Hospital, Drammen, Norway) were obtained by density
gradient centrifugation (Lymphoprep, Nycomed, Nor-
way). Monocyte-derived DCs were generated under
serum-free conditions from the adherent fraction of
PBMCs cultured in six-well plates at a density of 4 × 106
cells/ml for 1.5 h at 37°C in 3 ml CellGro DC medium
(CellGenix, Freiburg, Germany). Non-adherent cells were
collected and frozen for later use as responder cells.
Adherent cells were cultured in 3 ml CellGro DC medium,
supplemented with 800 U/ml GM-CSF and 10 ng/ml IL-4
every second day, until day 5 when maturation of DCs
was induced by addition of maturation cocktail (10 ng/ml
TNF- , 10 ng/ml IL-1 1000 U/ml IL-6 and 1 µg/ml PgE2)
for 24 h. Characterization of DC phenotype was done by
staining 0,5 × 106 cells with fluorochrome-labelled anti-
bodies against the Lin1 panel (CD3, CD14, CD19, CD16,
CD20, CD56), HLA-DR, CD1a, CD80, CD83, and CD86
(Becton Dickinson, San Jose, CA), and analyzing by FAC-
SCalibur flow cytometry (Becton Dickinson). The mAb
isotypes used were IgG1 FITC, IgG2a PE, IgG1 APC (Bec-
ton Dickinson, San Jose, CA).
Assessments of apoptosis and phagocytosis of apoptotic 
cells
Jurkat E6 cells obtained from American Type Culture Col-
lection (ATCC) were exposed to 1 µM staurosporin for 3
h to induce apoptosis. Apoptotic cell death was assessed
α.
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(Boehringer Manheim, Manheim, Germany). For assess-
ments of phagocytosis, Jurkat E6 cells were stained with
the green fluorescent dye PKH-67 (Sigma Aldrich) as
described in the kit manual, exposed to 1 µM staurosporin
for 3 h and incubated with immature DCs at a ratio of 3:1.
After 6 h, immature DCs were labelled with a red fluores-
cent antibody (mAb CD1a-PE). Phagocytosis of apoptotic
cells was measured quantitatively by flow cytometry. Sim-
ilarly, phagocytosis was visualized by confocal laser
microscopy (Leica TCS SP, equipped with HeNe and Ar
lasers) using apoptotic Jurkat E6 cells pre-stained with
PKH-26 red fluorescent dye (Sigma Aldrich) and DCs
stained with the green fluorescent dye PKH-67.
Preparation of Jurkat E6-cell mRNA and transfection of 
DCs
Jurkat E6 cells were used as a source of tumor material.
Total RNA was isolated from 20–25 × 106 cells using Tri-
zol Reagent as described by the manufacturer (Invitrogen,
Basel, Switzerland). Poly (A)+ mRNA was isolated from
total RNA using the GenoPrep Direct mRNA kit (GenoVi-
sion, Oslo, Norway). Purified mRNA was used fresh or
stored at -80°C until use. Transfection of DCs with mRNA
was performed as described previously [22], with minor
modifications. Briefly, immature DCs were washed once,
resuspended in RPMI-1640 (BIO-Whittaker, Walkersville,
MD) and placed on ice. 400 µl (approx. 2 × 106 cells) were
mixed with mRNA, transferred to a 4-mm-gap cuvette and
pulsed with a BTX ECM-830 square-wave electroporator
(Genetronics Inc., San Diego, CA) using instrument set-
tings 500 V and 1 ms. Transfected cells were incubated on
ice for 30 s followed by addition of 2.0 ml cold CellGro
DC medium supplemented with 10 ng/ml IL-4, 800 U/ml
GM-CSF and maturation cocktail (see above), and trans-
ferred to standard culturing conditions. Transfection with
EGFP-pCIpA102 mRNA (10 µg/400 µl) encoding the green
fluorescence protein [22] was used to verify transfection
efficiency.
Isolation of T-cell subsets CD4 and CD8
The Negative Isolation Kit (Dynal, Biotech) was used for
isolation of CD4 and CD8 T cells according to the manu-
facturer's protocol. Isolation was performed on day 7 after
in vitro priming, before setting up the ELISPOT assay.
Induction of primary T-cell responses
Mature DCs (0.3 × 106) expressing Jurkat E6-cell mRNA or
loaded with apoptotic Jurkat E6 cells, were co-cultured
with 3 × 106 autologous non-adherent PBMC for 7 days in
1.0 ml CellGro DC medium without serum, before setting
up the ELISPOT assay. The cultures were tested for INF-
production in an ELISPOT assay [27] following restimula-
tion for 24 h with thawed antigen-loaded DC using 0.5 ×
105, 1.0 × 105, 2.0 × 105 and 4.0 × 105 responding cells
and 0.5 × 104 DCs per well. Mock transfected DCs were
used as control. The assay was done in duplicate. Spots
were counted manually, and the frequency of reactive T
cells was calculated according to the formula: (spots with
transfected DC - spots with non transfected DC)/number
of T cells added.
Results
Generation of immature DCs and phagocytosis of 
apoptotic Jurkat E6 cells
Based on previous observations that immature DCs effi-
ciently capture antigens from the environment, we first
investigated the ability of immature DCs to similarly
phagocytose apoptotic Jurkat E6 cells. Immature DCs
were prepared from PBMC in the presence of IL-4 and
GM-CSF. To confirm generation of immature DCs, cells
were examined by flow cytometry for expression of line-
age and differentiation specific markers. The Lin 1 cocktail
contains antibodies to CD3, CD14, CD16, CD19, CD20,
and CD56 and differentiates DCs from other leukocytes
by their lack of staining with Lin1. In contrast, CD1a and
HLA-DR are expressed on immature DCs, and maturation
is revealed by increased expression of CD83, and the cos-
timulatory molecules CD80 and CD86. As shown in Fig.
1a the generated cells displayed the characteristic pheno-
type of immature DCs with high expression of CD1a and
HLA-DR, and low or no expression of CD80, CD83 and
CD86.
For induction of apoptosis, Jurkat E6 cells were treated
with staurosporin. In an independent series of experi-
ments, optimal early apoptosis was observed after 3 h
(data not shown) and early apoptotic cells were accord-
ingly used in all experiments. To verify apoptosis after 3 h
exposure to staurosporin, cells were stained with annexin
V-FLUOS and examined by flow cytometry. The assess-
ments showed that more than 90% of the cells were
annexin-V positive (Fig. 2).
To study uptake of apoptotic leukemia cells by immature
DCs, Jurkat E6 cells were stained with the red fluorescent
dye PKH-26 before induction of apoptosis. Immature DCs
were stained with the green fluorescent dye PKH-67.
Apoptotic Jurkat E6 cells were then co-incubated with
immature DCs for various periods of time to determine
the optimal conditions for internalization of apoptotic
Jurkat E6 cells. We observed that immature DCs ingested
apoptotic Jurkat E6 cells within 6 h of co-incubation.
Phagocytosed apoptotic Jurkat E6 cells (red stained) were
observed inside or in the process of being phagocytozed
by immature DCs (green stained) by confocal microscopy
(Fig. 3b).
Flow cytometry was used to further determine the effi-
ciency of DC loading with apoptotic leukemic cells. In
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stained with the green fluorescent dye PKH-67 and DCs
were identified by staining with PE-conjugated anti-
CD1a. Highly efficient uptake of apoptotic Jurkat E6 cells
was confirmed, since virtually all CD1a positive cells
showed green PKH-67 staining (Fig. 3a).
Following antigen loading, DCs were matured in the pres-
ence of pro-inflammatory cytokines for 24 h. Assessments
by flow cytometry confirmed that this treatment led to up-
regulation of CD83, and the co-stimulatory molecules
CD80 and CD86, in compliance with a mature DC phe-
notype (Fig. 1b).
Transfection of immature DC with mRNA from Jurkat E6 
cells
Transfection of cells with tumor-derived mRNA is an alter-
native method for loading of DCs with tumor antigens.
mRNA from the Jurkat E6 cells was isolated and electropo-
rated into DCs according to previously optimized meth-
ods [22]. Following this protocol, optimal conditions for
electroporation were 500 volt and 1 ms when using a 4-
mm-gap cuvette. These conditions produced both effi-
cient transfections (142 × background fluorescence; Fig.
4) and a survival rate indistinguishable from untrans-
fected cells (data not shown). The transfected DCs were
matured as described above and induction of the charac-
teristic phenotype was confirmed by flow cytometry (Fig.
1c).
Phenotype of generated DCsFigure 1
Phenotype of generated DCs. Expression of antigens were determined by flow cytometry (a) Before loading with tumor anti-
gens (b) After loading with apoptotic Jurkat E6-cells and following maturation with TNFα, IL1β, IL6 and PgE2 for 24 h and (c) 
After transfection with Jurkat E6-cell mRNA and maturation for 24 h. The histograms show staining with the appropriate mAb.
Staurosporin-induced apoptosis of Jurkat E6-cellsFigure 2
Staurosporin-induced apoptosis of Jurkat E6-cells. T cells 
were cultured for 3 h with 1 µM staurosporin and examined 
by Annexin V-FLUOS staining and flow cytometry.Page 4 of 10
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ELISPOT assay of INF-γ producing cells is the method of
choice for assessments of T-cell responses against cancer
vaccines representing a heterogeneous mixture of anti-
gens. This assay measures in a quantitative way the
number of reactive T cells in pre and post-vaccination
samples and thus directly relates the effect of vaccination
to in-vivo expansion of reactive T cells. Autologous T cells
were stimulated with tumour-mRNA transfected DCs and
with DCs loaded with apoptotic Jurkat E6 cells. Fig. 5
shows the results from experiments with cells derived
from three different donors. In all experiments a specific
T-cell response against antigen-loaded DCs as compared
to control DCs (mock transfected/non-loaded) could be
demonstrated. No clear-cut difference between the two
modes of antigen-loading was observed. In all experi-
ments with un-fractionated T cells, we also observed T-cell
reactivity against control DCs. This background com-
pletely obscured the specific response if in vitro priming
was performed in the presence of exogenously added
recombinant human IL-2 (results not shown). Antigen
loading of DC by mRNA transfection and phagocytosis
will introduce the Jurkat antigens into two different anti-
gen processing pathways, cytosolic expression and
Phagocytosis of apoptotic Jurkat E6 cells by immature DCsFigure 3
Phagocytosis of apoptotic Jurkat E6 cells by immature DCs. At day 5 of culture, DCs were co-cultivated with apoptotic Jurkat 
E6 cells, previously labelled with green fluorescent dye. (a) Flow cytometry of immature DCs stained with anti CD1a-PE and 
apoptotic Jurkat E6 cells stained with PKH-67 green. (b) Confocal microscopy analysis shows the presence of intracellular 
apoptotic cells labelled with PKH-26 red within DCs labelled with PKH-67 green (yellow cell, arrow) or in the process of being 
phagocytized (yellow and red cell, arrow).Page 5 of 10
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processing for phagocytosed apoptotic cells. As a result,
one might expect that mRNA loading would preferentially
result in activation of specific CD8+ CTLs, while loading
with apoptotic cells would mainly result in activation of
specific CD4+ Th1 cells. To investigate if this was the case,
we separated the responding T-cell population into a
CD4+ containing fraction and a CD8+ containing fraction
using negative selection with Dynabeads coated with CD8
and CD4 antibodies respectively. The results shown in Fig.
5 demonstrate that a specific Th1 response was obtained
in all donors and that both methods of loading resulted in
a Th1 response. The frequency of specific Th1 cells varied
between donors, with a trend indicating that mRNA load-
ing in general is more efficient than apoptotic cells in
priming of a Th1 response. The results depicted in Fig. 5
clearly show that relatively high frequencies of specific
CTLs can be generated in all donors and that both meth-
ods of antigen-loading result in CTL priming. In donor 2
and 3, mRNA loading was clearly superior to apoptotic
cells, indicating that expression of mRNA-encoded anti-
gens more efficiently entered the proteasomal pathway for
processing of HLA class I restricted antigens.
Discussion
Immunotherapy for childhood leukemia has the potential
to contribute to long-term control or cure of the disease.
Until now immunotherapeutic approaches for leukemia
have been limited to trials of cytokine therapy [3]. Further
development of biologically based treatments may prove
to be effective in therapy of patients suffering from this
disease. Several forms of DC-mediated immunotherapy
are currently being investigated using a wide variety of
vaccination protocols summarized in [28]. Two very
important issues are the choice of antigen and the method
of antigen loading. In the present study we have chosen to
use the complex antigen mixture represented by whole
tumor cells. Reports comparing the ability of apoptotic
and necrotic cells to induce DC maturation [29] found
that incubation of DCs with necrotic, but not apoptotic,
tumor cell lines induce maturation. However, other
reports concluded that incubation with apoptotic cells is
sufficient to induce DC maturation [30-34]. In our study
we have used apoptotic cells, and the requirement for DC
maturation signals was provided by a standardized matu-
ration cocktail. We accordingly analyzed human mono-
cyte-derived DCs for their ability to: (a) take up apoptotic
leukemia cells and express transfected mRNA, (b) express
a mature phenotype following tumour-antigen capture
and culture in maturation cocktail and (c) prime un-frac-
tionated T cells as well as the CD4+ and CD8+ T-cell
subsets. Due to the complexity of the antigens represented
by the allogeneic tumor cells, the aim of these model
experiments was not to use this allogeneic system to prove
that we could elicit tumour specific T-cell responses in this
way, but to provide data to demonstrate efficient antigen
transfer and compare the relative efficacy of DCs loaded
by the two different procedures, in eliciting complex T-cell
responses. Our results demonstrate that immature DCs
can efficiently take up apoptotic Jurkat E6 cells, and that
phagocytosis was mainly confined to the CD1a+ subset of
immature DC. Furthermore, support for expression of
transfected mRNA derived from the allogeneic leukemia
cell line is indirectly provided by its ability to prime T-cell
responses specific for transfected cells. We also show that
the two different methods of antigen-loading did not
result in any apparent differences in the phenotype of the
mature DCs. In terms of immune responses both methods
of antigen loading produced DCs capable of inducing
mRNA transfectation of DCsFigure 4
mRNA transfectation of DCs. (a) Flow cytometric analysis of 
DCs after transfection with EGFP/pCIpA102 mRNA (10 µg/
400 µl) by square-wave electroporation and maturation for 
24 h in medium with maturation cocktail. Control cells were 
mock electroporated without mRNA. (b) Fluorescence 
microscopy of DCs 24 h after transfection with EGFP/
pCIpA102 mRNA.Page 6 of 10
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loaded with tumour-mRNA in general were most potent
in inducing T-cell responses.
We observed that the frequencies of induced INF-γ pro-
ducing T cells depended on the individual donor, the
method of antigen-loading and the subset of T cells stud-
ied. Such variations are not surprising, since the model
system used employs allogeneic cells and no effort was
ELISPOT analysis of T-cell activationFigure 5
ELISPOT analysis of T-cell activation. T cells were stimulated with DCs loaded with tumour antigen (mRNA or apoptotic cells) 
or control DCs as indicated. (a) Mean number of IFN-γ positive spots obtained with the indicated numbers of un-fractionated 
T cells, and CD4+ and CD8+ T-cell subsets from individual donors. (b) Frequency of reactive T cells. The data represent mean 
values of all donors calculated by the formula: [(spots loaded DC - spots control DC)/105 T cells].

γPage 7 of 10
(page number not for citation purposes)
BMC Cancer 2005, 5:20 http://www.biomedcentral.com/1471-2407/5/20done to HLA match the blood donors with the Jurkat cell
line in these experiments. Since the experimental system
is based on the use of an allogeneic cell line, we expect
multiple antigens, encoded by a broad array of
polymorphisms, including other HLA alleles to be
involved. We have therefore taken advantage of the
genetic differences between responding cells and the leu-
kaemia cell line by using the combined repertoires of
membrane expressed and cross presented allo-antigens as
a sensitive readout for immunological response in our
experiments.
We expected that the two different procedures would pro-
vide some differences in loading of HLA molecules with
tumour-derived antigens and subsequently in the
responding T-cell subsets. According to the current
dogma, processed peptides from phagocytosed apoptotic
cells would be directed to HLA class I molecules by a proc-
ess known as cross-presentation and to HLA class II mole-
cules by the classical pathway. Cross-priming of CTL with
antitumor activity has been demonstrated with DCs
loaded with apoptotic tumour cells [19,21,35]. Specifi-
cally, Schnurr et al. demonstrated the antigens from apop-
totic pancreatic carcinoma cell lines, either in form of
whole cells or as released particles, were potent in induc-
ing CTL-cell priming and activation by DC. In addition,
Hoffman et al. reported stronger CTL responses with
apoptotic tumour cells in a squamous cell carcinoma
model. The enhanced CTL activation by antigens from
apoptotic cells may be attributed to several mechanisms.
After ingestion, most particulated antigens requiring
phagocytosis are digested into peptides associating with
HLA class-II molecules in the endocytic compartments
and are presented to T-helper cells [36]. Conversely, scav-
enger receptor-mediated phagocytosis of apoptotic
tumour cells allows antigens to gain access to HLA class-I
compartments, resulting in cross-presentation of the anti-
gens to CTL [20]. In addition, enhanced CTL responses to
tumours might be mediated by heat shock proteins
expressed by stress induced apoptotic tumour cells [37].
On the basis of this theoretical background and reported
observations [21,31] we believe that antigen preparations
from apoptotic tumour cells can also represent an alterna-
tive in DC-based tumour vaccines. On the other hand,
tumour mRNA expressed in DCs would be processed for
presentation by HLA class I molecules. In accordance with
this, DCs loaded with apoptotic leukaemia cells stimu-
lated both CD4+ and CD8 positive T cells and mRNA
loaded DCs were superior in inducing CD8+ T-cell
responses [38,39]. Interestingly, mRNA-loaded DCs were
also able to induce specific CD4+ T-cell responses in all
donors tested, suggesting some leakage of endogenously
produced proteins into the lysosomal antigen-processing
compartments. Similar results have recently been pub-
lished by Su et al., who demonstrated a significant Th
response against the defined tumour antigen hTERT fol-
lowing in vitro stimulation of un-fractionated T cells with
hTERT mRNA transfected DC. The Th response could be
further augmented by targeting the antigen to the lyso-
somal compartment using mRNA encoding a chimeric
hTERT/lysosome-associated membrane protein (LAMP-1)
protein.
The aim of the present study was to determine if loading
of DCs with antigens derived from a tumour cell line,
either as apoptotic cells or as mRNA would provide a basis
for an efficient vaccine, using ELISPOT as a read-out of
immune responses. It has been shown that DCs trans-
fected with antigens encoded in tumor mRNA is capable
of inducing potent T-cell responses against tumour-spe-
cific epitopes [40]. While protein antigens from tumour
lysate are rapidly proteolysed following endocytosis by
antigen-presenting cells, model experiments using mRNA
encoding a fluorescent protein, EGFP, has shown that pro-
tein is still being produced 24 hrs after transfection of
DCs, with peak expression after 48 hrs [22]. Thus, tumor
mRNA transfected DCs may not only represent a potent
strategy for CTL priming but may also represent a general
method for DC-based vaccines. In vaccine preparations
using DCs, mRNA is thus preferable to a protein lysate.
Similarly, immunization with DCs loaded with mRNA
from leukaemia cells could represent a feasible approach
in treatment of these cancers. It is now widely accepted
that not only CTLs but also CD4 (+) T-helper cells are crit-
ical to the generation and maintenance of potent antitu-
mor responses in vivo. In this context, our observation
and that of others demonstrating that DCs loaded with
mRNA also are equally capable of inducing Th responses
strongly argue in favour of this type of vaccination. Our
preclinical results further support that vaccination of
leukemia patients with tumour-mRNA transfected autolo-
gous DCs should be clinically evaluated as therapeutic
strategy.
Conclusion
In our study we demonstrate that both DCs loaded with
apoptotic Jurkat E6 cells or transfected with mRNA iso-
lated from Jurkat E6 cells, can induce T-helper and CTL
responses against antigens derived from allogeneic
leukemic T-cells. We also show that the two different
methods of antigen-loading did not result in any apparent
differences in the phenotype of the mature DCs. In terms
of immune responses both methods of antigen loading
produced DCs capable of inducing INF-  secreting T
cells. However, it appeared that DCs loaded with tumour
mRNA in general were most potent in inducing T-cell
responses.
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